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A B S T R A C T
A retrospective medical chart review was performed on 65 HIV-infected patients with tuberculosis hospitalized be-
tween 1986 and 2006 at the University Hospital for Infectious Diseases »Dr Fran Mihaljevi}«, Zagreb. Thirty two pa-
tients presented with pulmonary involvement, 13 with extrapulmonary, and 20 patients had disseminated tuberculosis.
Forty five patients had an abnormal chest X-ray. Mycobacterium tuberculosis was identified in 35 (53.9%) patients. Ten
(15.3%) of 65 patients had already been receiving antiviral therapy, while another 31 (47.7%) initiated antiviral therapy
after antituberculosis therapy. Tuberculosis-associated immune reconstitution inflammatory syndrome was observed in
11/27 (40.7%) patients. Forty one patient received the standard six month course of antituberculous therapy, while in 12
patients the therapy was prolonged. Twenty one patient (32%) experienced an adverse event to antituberculosis drugs.
Twelve patients died (18.5%). After the introduction of highly active antiviral therapy (HAART) the mortality decreased.
The incidence of tuberculosis in HIV-infected patients in Croatia is increasing, and tuberculosis is still an important op-
portunistic infection in our HIV-infected patients.
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Introduction
Tuberculosis and human immunodeficiency virus
(HIV) are the leading causes of death from infectious dis-
eases among adults in the world1. Patients with HIV in-
fection are at increased risk for tuberculosis, and tuber-
culosis is a major cause of morbidity and mortality in
HIV-infected patients, particularly in the developing
world. Parallel to the increasing use of highly active
antiretroviral therapy (HAART), a substantial decrease
in the incidence of HIV-associated illnesses has been ob-
served, as well as tuberculosis. However, some patients
may not show an immunological response when treated
with antiretroviral therapy and therefore remain at high
risk of developing opportunistic infections2. On the other
side, cases of tuberculosis with deterioration were re-
ported also in patients showing an augmented immuno-
logical and/or virological response to therapy, known as
the immune reconstitution inflammatory syndrome -IRIS3.
HIV infection is still relatively uncommon in Croatia.
The majority of cases are believed to be imported, hence
Croatia can be defined as a »pattern III country«4. The
Epidemiology Service of the Croatian National Institute
of Public Health Zagreb reported 553 HIV-infected per-
sons in Croatia in the period 1985 to 2005. The first cases
of AIDS have been diagnosed in 1986 and until December
2005 a total of 239 AIDS patients were treated at the
University Hospital for Infectious Diseases »Dr. Fran
Mihaljevi}» Zagreb. Out of them 118 AIDS patients died.
The incidence of tuberculosis cases in Croatia decreased
during the last twenty years. In 2005 there were 1,144
newly detected tuberculosis cases in Croatia rendering
an incidence of 26 rates per 100,000 inhabitants.
The aim of our study was to describe the clinical fea-
tures of tuberculosis in HIV-infected patients in Croatia.
Patients and Methods
We retrospectively analyzed all HIV-infected patients
with tuberculosis hospitalized at the University Hospital
for Infectious Diseases »Dr. Fran Mihaljevi}», Zagreb, be-
tween January 1, 1986 through December 31, 2005. A
case of tuberculosis was defined as the presence of cli-
nicoradiological features and histological findings sug-
gestive of tuberculosis, confirmed by the isolation of My-
cobacterium tuberculosis in culture or by clinical and
radiological improvement in response to specific antitu-
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beruculosis therapy5. Culture negative cases were in-
cluded only if antituberculous therapy was given for at
least 6-months. Disseminated tuberculosis indicated the
spread of disease from lungs to other organs of the body
by blood or lymphatic system. AIDS-defining illnesses
were defined according to the 1993 Centers for Disease
Control and Prevention revised case definition6. The pa-
tients were tested for tuberculin reactivity with 5 tuber-
culin units of purified protein derivate (PPD), using the
Mantoux procedure. An induration in response to PPD of
at least 5 mm was considered a positive response. IRIS
was classified according to the French et al.7. Viral load
and CD4 cell count were recorded from medical notes at
tuberculosis diagnosis. HAART was defined as the use of
at least 3 antiretroviral drugs in combination.
We analysed demographic and epidemiological data
(age, sex, place of birth, place of residence, HIV transmis-
sion category, AIDS-defining illnesses, current antiretro-
viral therapy regimen, date of tuberculosis diagnosis),
laboratory findings (CD4 cell count, plasma viral load
/HIV-RNA values/, tuberculin skin test status, chest X-
ray), microbiology examination (sputum culture, urine
culture, culture of lymph node), locality of disease (pul-
monary, extrapulmonary, disseminated) course and out-
come of the disease (antituberculous therapy, adverse
events, IRIS, recovery or death).
Statistical analysis
To describe the internal data, median and range are
given. For categorical variables percentages are used.
Differences in categorical variables were analyzed with
the use of Fisher's exact two-tailed test. Comparison be-
tween continuous variables was done by the Mann-Wit-
ney test (two groups), and Kruskall-Wallis test (three
groups). The results were considered significant at p<
0.05. Survival times were compared by the Cox propor-
tional hazard model. Patients alive were censored as of
June 1st 2006. All tests were performed with the STA-
TISTICA for Windows software package.
Results
During the last two decades the incidence of tubercu-
losis in Croatia has declined from 65 cases per 100,000 in
the period 1986–1990 to 31 cases per 100,000 in the pe-
riod 2001–2005 (Table 1). On the other side, in the same
period the number of newly diagnosed HIV-infected per-
sons increased from 62 to 230 (Table 1). Out of 553
HIV-infected patients in Croatia, 65 (11.8%) were coin-
fected with tuberculosis. The number of tuberculosis
cases in HIV-infected individuals increased from 1.5 ca-
ses per 1,000 tuberculosis cases in the period from 1986
to 1990 to 9.1 cases per 1,000 in the period from 2000–
2005.
We found 17 different major opportunistic infections
in our 239 AIDS patients (Table 2). Tuberculosis is the
second most frequent opportunistic infection, after Pneu-
mocystis jiroveci pneumonia (PCP).
The demographic and baseline characteristics of the
65 individuals with tuberculosis are shown in Table 3.
The median age of patients was 40 years, 87.7% were
men. Sixty patients (92.3%) were born in Croatia, of
whom 27 resided in the Mediterranean coastal region, 25
in the Center mountains, and 8 in the Pannonian conti-
nental region of Croatia. The leading risk factor for HIV
acquisition was heterosexual sex and sex between men
(84.6%).
Thirty two patients presented with pulmonary in-
volvement, 13 with extrapulmonary (lymph nodes 10,
CNS 2, liver 1), and 20 patients had disseminated tuber-
culosis (Table 4). The median CD4 cell count and viral
load at the time of tuberculosis diagnosis were 57 cells/
mL and 229.082 copies/L, respectively. Patients with
pulmonary form of disease had a median of 57 CD4
cells/L (range, 3–602 cells/mL), extrapulmonary 152
cells/L (range, 13–648 cells/L), and disseminated dis-
ease 42 CD4 cells/mL (range, 1–566 cells/L). Patients
with pulmonary and disseminated form of illness had a
lower CD4 cell count than extrapulmonary tuberculosis,
but the difference was not statistically significant (p=
0.12). Forty five (71.4%) patients had an abnormal chest
X-ray; 15 had a diffuse and 16 had a focal infiltrate.
Other pulmonary abnormalities included miliary, nodu-
lar, and reticular patterns of the infiltrates. Five patients
had cavities, while pleural effusion was recorded in seven
patients.
The average period from the first symptoms to diag-
nosis of tuberculosis was 18 days. Out of 65 patients M.
tuberculosis was identified in 35 (53.9%) patients. There
were no drug-resistant strains of M. tuberculosis. Twen-
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TABLE 1
INCIDENCE OF TUBERCULOSIS AND HIV-ASSOCIATED TUBERCULOSIS IN CROATIA FROM 1986 TO 2005*
Years
New cases of TB
in total population
Incidence/100.000
individuals
Newly diagnosis
HIV-infected patients
Number of
TB in HIV-infected patients
1986–1990 15,091 65 62 5
1991–1995 10,957 46 96 14
1996–2000 9,746 41 155 20
2000–2005 6,910 31 230 26
* Data from Epidemiology Service, Croatian National Institute of Public Health Tuberculosis Register.
In 1985 were diagnosed 10 HIV-infected patients
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ty one patient had sputum-culture proven M. tuberculo-
sis (five were smear positive), while in 10 patients bacte-
rium was cultured from the lymph node. Two patients
had positive urine culture for M. tuberculosis, while in
one patient the bacterium was detected in pleural effu-
sion and spinal fluid, respectively. Patients with microbi-
ological confirmed disease had a median of 125 CD4
cells/mL (range, 1–648 cells/L), while patients with un-
confirmed disease had 54 CD4 cells/L (range, 1–602
cells/L) (p=0.42).
At the time of tuberculosis diagnosis, twenty eight pa-
tients had another AIDS-defining illness, 22 esophageal
candidiasis, three PCP, and one patient had recurrent-
bacterial pneumonia, Kaposi's sarcoma and Cryptococco-
cus meningitis, respectively. Ten (15.3%) of 65 patients
had already been receiving antiviral therapy, while an-
other 31 (47.7%) initiated antiviral therapy after anti-
tuberculosis therapy, median of 27 days (range 1–96
days). Of the 41 patient who received antiretroviral ther-
apy, 5 recieved one drug (zidovudine), 9 two drugs (zi-
dovudine plus didanosine), and 27 HAART. Seven
HAART regimens, involving nine different combinations
of drugs were prescribed. Twelve patients received a
combination of nucleoside reverse transcriptase inhibi-
tor with non-nucleoside reverse transcriptase inhibitor,
while other 15 nucleoside reverse transcriptase inhibi-
tors with protease inhibitor. Eleven of 27 (40.7%) pa-
tients receiving HAART were diagnosed with IRIS. IRIS
occured at a median of 17 days (range 8–24) after initiat-
ing HAART. Seven of 11 patients who developed IRIS
had disseminated tuberculosis.
Of the 65 patients, 53 completed therapy whereas 12
(18.4%) patients died during treatment. Tuberculosis
was diagnosed prior to 1999 (HAART was introduced in
Croatia in April, 1998) in 32 patients, while in 33 pa-
tients after that period. Of the 32 patients diagnosed be-
fore 1999, 19 died and of 33 patients diagnosed in the pe-
riod 1999–2005, 5 died. The hazard ratio of death was
0.27 (95% confidence interval 0.1 to 0.7) lower in the pe-
riod 1999–2005 compared to the period 1986–1998 (p=
0.009). Of the 53 patients who completed therapy, 41 re-
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TABLE 2
TUBERCULOSIS CASES AND OTHER OPPORTUNISTIC INFECTIONS (AIDS-DEFINING ILLNESSES) IN 239 AIDS PATIENTS TREATED
AT THE UNIVERSITY HOSPITAL FOR INFECTIOUS DISEASES »DR. FRAN MIHALJEVI]«, ZAGREB FROM 1986 TO 2005
Opportunistic infections No %
Pneumocystis jiroveci pneumonia (PCP) 70 15.8
Mycobacterium tuberculosis 65 14.7
Candidiasis of esophagus, trachea, bronchi or lungs 60 13.6
HIV-encephalopathy 48 10.8
Cytomegalovirus (CMV) chorioretinitis 29 6.6
HIV wasting syndrome 28 6.3
Kaposi's sarcoma 27 6.1
Cryptococcosis extrapulmonary 25 5.6
Malignant lymphoma 22 5.0
Toxoplasmosis of brain 19 4.3
Central nervous system diseases, undetermined 16 3.6
Progressive multifocal leucoencephalopathy 11 2.5
Herpes simplex virus ulcers (duration > 1 month) 9 2.0
Recurrent bacterial pneumonia 5 1.1
CMV – other location 4 0.9
Cervical malignancies 3 0.7
Salmonella bacteriaemia (> 2 episodes) 2 0.5
Summary 443 100.00
TABLE 3
DEMOGRAPHIC AND BASELINE CHARACTERISTICS OF
65 PATIENTS WITH HIV-ASSOCIATED TUBERCULOSIS
Median age (range) years 40 (16–74)
Sex, male (%) 57 (87.7)
Place of birth (%)
Croatia 60 (92.3)
Other 5 (7.7)
Place of residence in Croatia (%)
Mediterranean coastal 27 (45.0)
Pannonian continental 8 (13.3)
Center mountains 25 (41.7)
HIV transmission category (%)
Injecting drug users 8 (12.3)
Man who have sex with man 27 (41.5)
Heterosexual 28 (43.1)
Other/undefined 2 (3.1)
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ceived the standard six months course, whereas 12 pa-
tients received prolonged treatment. The reason for a
prolonged tuberculosis course was tuberculosis meningi-
tis (1 patient) and disseminated disease (11 patients). In
our patients most commonly recommended regimen was
a four-drug combination of isoniazid, rifampin, pyra-
zinamide, and ethambutol given for the first 2 months,
and isoniazid and rifampin continued for another 4
months. Adverse events led to a cessation and modifica-
tion of their tuberculosis therapy in 21 (32.3%) patients.
The most common side effects noted were hepatitis (11
patients), gastrointestinal disturbances (7 patients), fe-
ver (6 patients) and rash (2 patients).
Discussion
Croatia is country with a moderate incidence of M. tu-
berculosis infection in the indigenous population and
with a relatively small number of HIV-infected persons.
The incidence of tuberculosis is much lower than in the
developing countries, but is higher than in the Western
European countries. The incidence of tuberculosis in
Croatia has been declining during the last two decades
nearly threefold, from 72 cases per 100,000 in 1986 to 26
cases per 100,000 inhabitants in 2005. On the other side,
the incidence of HIV infection had a slow increase over
time. Therefore, a relative rise in the number of HIV-re-
lated tuberculosis compared to non-HIV related tubercu-
losis in the last two decades is not surprising. Compari-
son of tuberculosis incidence in general populations and
HIV-infected persons shows that the incidence of tuber-
culosis is 20 to 30 times higher among HIV-positive per-
sons. We found that 14.7% of our AIDS patients had tu-
berculosis. In the USA about 5% of AIDS patients de-
veloped tuberculosis, while in the Western European
countries the frequency of tuberculosis in AIDS patients
has been estimated between 5 to 15%8. Much higher
numbers of AIDS patients contract tuberculosis in devel-
oping countries, where up to 50% of the total population
may be infected with M. tuberculosis9.
A significant proportion of our patients (72.7%) had a
negative skin test. It is not surprising because more than
half of our patients (50.5%) are in advanced immuno-
suppression (CD4 cell count <100/L). With the recom-
mended cut-off point for HIV-infected patients of 5 mm
induration at 48 hours after intradermal injection of 5
units of PPD, skin testing is consistently negative only in
patients with advanced immunosuppression10.
About one half of our patients had pulmonary in-
volvement. Several other studies reported pulmonary in-
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TABLE 4
CLINICAL, RADIOLOGICAL AND LABORATORY CHARACTERISTICS OF 65 PATIENTS WITH HIV-ASSOCIATED TUBERCULOSIS AT THE
TIME OF TUBERCULOSIS DIAGNOSIS
Tuberculin skin test status [n=44] (%)
Positive 12 (27.3)
Negative 32 (72.7)
Site (%)
Pulmonary 32 (49.2)
Extrapulmonary 13 (20.0)
Disseminated 20 (30.8)
CD4+ T lymphocytes ´ 106/l [n=56] (range) 56.5 (1–648)
 500(%) 4 (7.1)
200–499 8 (14.3)
0–199 44 (78.6)
Plasma viral load – RNA copies/ml [n=35] (range) 299.082 (2.540–4,960.000)
< 100.000/mL (%) 9 (25.7)
100.000–500.000/mL 12 (34.3)
500.001–1,000.000/mL 8 (22.9)
> 1,000.000/mL 6 (17.1)
Chest X-ray pattern (%)
Normal 18 (27.7)
Focal infiltrate 15 (23.1)
Diffuse infiltrates 12 (18.5)
Pleural effusion 7 (10.8)
Cavities 5 (7.7)
Nodular pattern 3 (4.6)
Reticular pattern 3 (4.6)
Miliary 2 (3.1)
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volvement in 70–90% of the total number of HIV-infected
patients with tuberculosis11,12. Jones et al. found that
extrapulmonary tuberculosis becomes more common as
the CD4+ count falls10. Low CD4 cells count in dissemi-
nated form of illness is to be expected as well. Pulmonary
tuberculosis infection has become more commonly re-
ported in the post-HAART era, possibly resulting from
increased cases due to IRIS.
HIV-infected patients with pulmonary tuberculosis
exhibit atypical radiological presentation and negative
sputum smear more frequently than their HIV-negative
counterparts13,14. Chest X-ray findings in HIV-associated
tuberculosis vary with the CD4+ count. The upper lobe
infiltrates, which are typical of reactivated disease, occur
in approximately one third of patients13. However, in
HIV-infected patients with pulmonary tuberculosis chest
X-ray may be normal, especially in those with advanced
immunosuppression. In autopsy studies, up to 50% of
HIV-related tuberculosis deaths go undiagnosed15,16.
More than half (53.8%) of our patients were already
diagnosed with active tuberculosis when HIV testing was
performed.
In Croatia, a dual combination antiretroviral therapy
was introduced during 1995 and triple combination with
protease inhibitors in April 1998. In our study, the risk of
death decreased by 73% among HIV-infected persons
treated in the HAART era. However, a significant propor-
tion of HIV-infected patients presented with tuberculosis
while already undergoing HAART17.
The frequency of tuberculosis IRIS among patients in
the present study was 40.7%. The majority of these pa-
tients developed IRIS after the second week of initiating
HAART. Previous studies reported IRIS rate ranging
from 11% to 43%18,19. IRIS presents within the first 2
months of HAART, usually in the first few weeks20. IRIS
has symptoms overlapping with worsening tuberculosis
and drug reactions, and can be life-threatening. The ma-
jority of patients with IRIS had a disseminated tubercu-
losis (7/11). Other studies demonstrated that extrapul-
monary tuberculosis was one of the possible risk factors
associated with the occurrence of IRIS18,21.
Although highly effective therapy for both HIV and
tuberculosis is available, concomitant administration is
difficult. To date, the optimal time to start HAART in
HIV/tuberculosis coinfected patients is not known. Phy-
sicians and patients have to balance the risk of HIV pro-
gression against the risk of having to discontinue thera-
pies because of toxicities, side effects or unforeseen drug/
drug interaction22. Patients who start antiretroviral the-
rapy early in their tuberculosis treatment can be predis-
posed to IRIS. WHO guidelines suggest starting antire-
troviral drugs within 2 months of tuberculosis treatment
at a CD4 count between 50 to 200 per µL and for
extrapulmonary tuberculosis or other manifestation of
severe immunosuppression23. For patients with CD4
counts less than 50 per mL, treatment initiation is ad-
vised within 2 weeks23.
The same treatment guidelines as for HIV-uninfected
patients can be applied to HIV-infected patients with tu-
berculosis. Several studies recommending prolonged the-
rapy, particularly in patients with disseminated disea-
se24,25. However, there is now evidence that the standard
6-month treatment course may be adequate for all forms
of HIV-related tuberculosis, except central nervous sys-
tem involvement26,27. Prolonged therapy is recommended
only for patients with a slow or suboptimal response. Be-
tween 6% and 24% of patients require a modified drug
regimen because of intolerance, usually to isoniazid or,
even more frequently to rifampin28. Use of rifabutin may
be an alternative to therapy with rifampin.
The decline in tuberculosis-related mortality in our
patients (73%) in the HAART era is almost identical to
the findings reported by Dean et al.29 where the mortal-
ity fell by 72% after the introduction of HAART29. Tuber-
culosis case-fatality rates in Africa are 16–35% in HIV-in-
fected individuals30.
In conclusion, tuberculosis is still one of the leading
opportunistic infections in our HIV-infected patients.
The proportion of HIV-related tuberculosis compared to
non-HIV related tuberculosis is slowly increasing in the
last two decades, however, mainly because of a decline of
non-HIV related tuberculosis. After the introduction of
HAART the mortality in HIV-associated tuberculosis de-
creased substantially.
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TUBERKULOZA U BOLESNIKA ZARA@ENIH HIV-OM U HRVATSKOJ
U RAZDOBLJU OD 1986. DO 2005. GOD.
S A @ E T A K
Rad se temelji na retrospektivnoj analizi 65 HIV-pozitivnih bolesnika s tuberkulozom koji su bili hospitalizirani u
Klinici za infektivne bolesti »Dr. Fran Mihaljevi}« u Zagrebu od 1986. do 2005. godine. Trideset i dva bolesnika su imala
plu}ni oblik bolesti, 13 izvanplu}ni, a 20 je imalo diseminiranu tuberkulozu. Patolo{ki nalaz na rendgenskoj slici plu}a
otkriven je u 45 bolesnika. Mycobaterium tuberculosis je dokazan u 53,9% bolesnika. Deset (15,3%) bolesnika je bilo na
antivirusnoj terapiji prije dijagnosticiranja tuberkuloze dok je antivirusna terapija uvedena u 31 (47,7%) bolesnika
nakon zapo~injanja lije~enja tuberkulostaticima. Imunorekonstruktivni inflamatorni sindrom je zabilje`en u 11/27
(40,7%) bolesnika. Standardno {esto mjese~no lije~enje provedeno je u 41 bolesnika, a 12 bolesnika lije~eno je dulje.
Nuspojave su zabilje`ene u 21 bolesnika. Umrlo je 12 (18,5%) bolesnika. Nakon uvo|ena visoko u~inkovite antire-
trovirusne terapije (HAART) smanjuje se smrtnost. Incidencija tuberkuloze u HIV-pozitivnih osoba u Hrvatskoj je u
porastu, a tuberkuloza je va`na oportunisti~ka infekcija u na{ih HIV-pozitivnih bolesnika.
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